

| 2026 editorial calendar |

	Q1 PRINT	Q2 DIGITAL	Q3 PRINT	Q4 DIGITAL
Ad closing (Tentative dates)	1/21/2026	4/8/2026	7/22/2026	11/30/2026
Artwork due (Tentative dates)	1/23/2026	4/10/2026	7/24/2026	12/2/2026
R&D	Delivery methods: viral vs nonviral Cell source: autologous vs allogeneic In vivo delivery	Payloads: CAR-T, CRISPR, siRNA Clinical trial design Traversing the gap between academic labs and product development	Medical devices for regenerative medicine Source material: apheresis/whole blood Data collection/management	Ex-US clinical trials Resolving clinical holds Disease modeling
QA/QC	Microbial contamination control PAT/real-time monitoring	Viral controls GMP in hospital settings	Quality risk assessment Product characterization	Cryopreservation Imaging and microscopy
Regulatory compliance	International regulatory harmonization Expanded access programs	CMC data challenges FDA platform designation	CGMP compliance Potency assurance strategy	Regulatory tools to expedite access IND preparation
Scale-up/manufacturing	In-house vs outsourcing LNP production AI in manufacturing	Facility design Role of CDMOs in manufacturing innovation Optimizing viral vectors	Bioreactors/cell expansion Supply chain logistics Automated manufacturing models	Ex vivo cell therapy manufacturing Manufacturing models: centralized vs decentralized Workforce training
Market outlook / Future trends	Investment outlook Commercial viability	Emerging CGT hubs Accessibility	Patient perspectives Uncertainty in U.S. health agencies	Transparency and communication Emerging longevity medicine space
Show / conferences	Advanced Therapies Week Interphex ASGCT ISCGT BIO International Convention		Advanced Therapies Europe Meeting on the Mesa CPHI Worldwide AAPS PharmSci360 Advanced Therapies World	

*Show dates listed are as of Aug. 2025. Dates and topics are subject to change without notice. Some shows have not announced dates at the time of publishing and are estimated.
 •To submit editorial for online publication or for author guidelines, connect with Editor-in-Chief, Karen Langhauser: klanghauser@comparenetworks.com.
 •Share your press releases and product announcements with us at: news@cellgenetherapyreview.com

Editorial advisory board

Mark Flower

Vice President of Business Development,
Cell and Gene Technologies
AGC Biologics

Carol Houts

Chief Strategy and Commercial Officer
GermFree

Claudia Lin, Ph.D.

Executive Vice President
Pharmatech Associates —a USP company

Jeffrey Martin, Ph.D.

Founder
Oncoleader

Carl Schoellhammer, Ph.D.

Partner
DeciBio Consulting

Lara Ionescu Silverman, Ph.D.

Principal Consultant
LIS BioConsulting

Sanjin Zvonic, Ph.D.

Senior Vice President, Business
Development & Practice Expert
Dark Horse Consulting